## Tagretin (bexarotene) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

**Instructions:** Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

			URGEN1		
MEMBER INFORMATION					
LAST NAME:		FIRST NAME:			
PHONE NUMBER:		DATE OF BIRTH:			
STREET ADDRESS:					
CITY:		STATE: ZIP CODE:			
PATIENT INSURANCE ID NUMBER:					
MALE FEMALE HEIGHT (IN/CM): WEIGHT (LB/KG): ALLERGIES:  F YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE):					
AUTHORIZED REPRESENTATIVE'S PHONE NUMBER:					
PRESCRIBER INFORMATION					
LAST NAME:		FIRST NAME:			
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:			
NPI NUMBER:		DEA NUMBER:			
PHONE NUMBER:		FAX NUMBER:			
STREET ADDRESS:					
CITY:		STATE: ZIP CODE:			
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:			
MEDICATION OR MEDICAL DISPENSING INFORMATION					
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:		
■ NEW THERAPY	RENEWAL	IF RENEWAL: DATE THERAPY	INITIATED:		
DURATION OF THERAPY (SPECIFIC DATES):					

Continued on next page.



## Tagretin (bexarotene) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	/IBER'S LAST NAME: MEMBER'S FIRST NAME:	
1. HAS THE PATIENT TRIED ANY OTH	ER MEDICATIONS FOR THIS CONDITION	? YES (if yes, complete below) NO
MEDICATION/THERAPY (SPECIFY	<b>DURATION OF THERAPY</b> (SPECIFY	RESPONSE/REASON FOR
DRUG NAME AND DOSAGE):	DATES):	FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
□ T-cell lymphoma		
□ Other diagnosis:	ICD-10	
3. REQUIRED CLINICAL INFORMATIO	N: PLEASE PROVIDE ALL RELEVANT CLIN	ICAL INFORMATION TO SUPPORT A
PRIOR AUTHORIZATION.		
Clinical Information:		
Does the patient have a diagnosis of	cutaneous manifestations of T-cell lym	phoma (CTCL) (e.g., mycosis
fungoides/Sezary syndrome)?   ☐ Yes		
Was Targretin prescribed by an onco	ologist or dermatologist?   Yes   No	
For oral Targretin (bexarotene):		
Is the patient refractory to at least o	ne systemic therapy?   Yes   No	
Please provide dates of service.		
For topical Targretin:		
	and failure of topical Valchlor? $\Box$ Yes $\Box$ I	No
Please provide dates of service		
Are there any other comments, diag	noses, symptoms, medications tried or	failed, and/or any other information the
physician feels is important to this re		•
	are covered on all plans. This request ma	ay be denied unless all required
information is received.		
	·	pest of my knowledge. I understand that
	up or its designees may perform a routin	•
information necessary to verify the a	ccuracy of the information reported on t	this form.
Prescriber Signature or Electronic I.E	D. Verification:	Date:
•	ccompanying this transmission contain confident	ial health information that is legally privileged. If
		oution, or action taken in reliance on the contents

**FAX THIS FORM TO: 800-424-7640** 

of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX)

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811



and arrange for the return or destruction of these documents.